search
obesity
Trends
- 1India moves to ban junk food sales around schools●India tightens school junk food rules amid obesity rise India proposes banning junk food sales in school canteens and wi
India has proposed banning junk food sales in school canteens and within 50 meters of schools, aiming to curb rising obesity and diabetes rates among children. The measures would restrict children's access to sugary drinks, chips and other unhealthy products during school hours and nearby, as health officials respond to growing concerns over childhood obesity across the country.
- 2GLP-1 drugs shift from obesity medicine to lifestyle products▼Once described as obesity medicines for 'patients,' GLP-1s are increasingly lifestyle drugs for 'customers'
Drugs like Ozempic and Wegovy were originally developed and described as obesity treatments for patients with medical need, but they are increasingly marketed and used as lifestyle drugs for customers seeking cosmetic or wellness benefits. Commentators note this reframing raises questions about access for people with genuine medical need, pricing, and how the pharmaceutical industry positions these medicines.
- 3Banning ultra-processed foods poses major hurdles for public schools●Banning ultra-processed foods brings major hurdles for public schools
Efforts to ban ultra-processed foods from public schools are running into significant practical obstacles, according to reporting highlighted by News-Medical. Schools face challenges around sourcing affordable alternatives, reworking contracts with food suppliers, and meeting nutrition standards on tight budgets. The debate touches on children's health, obesity prevention, and the feasibility of overhauling cafeteria menus at scale.
- 4Tirzepatide May Activate Brown Fat, Research Suggests▼Tirzepatide May Activate Brown Fat According to New Research
New research suggests tirzepatide, the weight-loss and diabetes drug sold as Mounjaro and Zepbound, may activate brown fat, a type of tissue that burns calories to generate heat. If confirmed, the finding could help explain the drug's effectiveness and open new avenues in obesity treatment. Coverage is so far limited, with fitness outlets picking up the claim and experts urging caution until results are published in full.